Elanco launches Befrena for canine allergic itch

Elanco has expanded its canine dermatology lineup with the phased U.S. launch of Befrena, a tirnovetmab injection approved by the USDA for dogs with allergic dermatitis and canine atopic dermatitis. The anti-IL-31 monoclonal antibody was approved in December 2025, and Elanco said on May 18, 2026, that select clinics are already using it through an Early Experience Program as broader commercialization ramps up. The company is positioning Befrena as an in-clinic option that starts controlling itch within 24 hours and is dosed every 6 to 8 weeks, with no age or weight restrictions on the label. USDA records list tirnovetmab under product code 958005, confirming its licensure as a canine biologic. (elanco.com)

Why it matters: For veterinary professionals, Befrena adds another monoclonal antibody option in a high-volume, high-frustration category where allergic skin disease often requires repeated visits, multimodal management, and careful client communication. AAHA noted it is the second injectable monoclonal antibody for allergic dermatitis in dogs in the U.S., joining Cytopoint, while recent allergic skin disease guidelines emphasize that atopy is a diagnosis of exclusion and that these cases often need long-term management rather than a one-time fix. USDA study summaries supporting licensure describe efficacy work in both an IL-31 pruritus model and a 213-dog field study, plus a 400-dog safety study with three doses given every 6 weeks, suggesting clinics will need to think about where Befrena fits alongside cytology, parasite control, infection management, diet trials, immunotherapy, JAK inhibitors, and existing biologics. (aaha.org)

What to watch: Watch for how quickly supply expands beyond the early-access sites, how practices position Befrena against existing itch therapies, and whether post-launch experience changes prescribing patterns during the 2026 allergy season. (nasdaq.com)